<MedlineCitation Status="Completed">
<MedlineID>10011868</MedlineID>
<PMID>217494</PMID>
<DateCreated>
<Year>1979</Year>
<Month>05</Month>
<Day>23</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>05</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0006-8993</ISSN>
<JournalIssue>
<Volume>165</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1979</Year>
<Month>Apr</Month>
<Day>13</Day>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>Pharmacological and immunological characterization of the Leu5 analogue of human beta-endorphin.</ArticleTitle>
<Pagination>
<MedlinePgn>311-9</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The potencies of beta h-endorphin, Met (O)5-beta h-endorphin, and synthetic Leu5-beta h-endorphin have been compared in three bioassays of opioid activity, and in two radioimmunoassays. In all assays, a peptide isolated from hemodialysates from a psychotic patient behaved like Leu5-beta h-endorphin; it has been distinguished unambiguously from beta h-endorphin and Met(O)5-beta h-endorphin. Leu5-beta h-endorphin was one-fifth as potent as beta h-endorphin in guinea pig ileum myenteric plexus, but was only slightly less active in mouse vas deferens and in guinea pig brain opiate receptor binding assay. The low cross-reactivity of Leu5-beta h-endorphin relative to beta h-endorphin with an antiserum raised to beta-endorphin suggests that the preferred solution conformations of these peptides are different. In all bioassays beta h-endorphin was 2- to 3-fold less potent than beta c-endorphin.</AbstractText>
</Abstract>
<AuthorList>
<Author>
<LastName>Cox</LastName>
<ForeName>B M</ForeName>
<Initials>BM</Initials>
</Author>
<Author>
<LastName>Ross</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author>
<LastName>Goldstein</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author>
<LastName>Palmour</LastName>
<ForeName>R M</ForeName>
<Initials>RM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>NETHERLANDS</Country>
<MedlineTA>Brain Res</MedlineTA>
<NlmUniqueID>0045503</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Endorphins</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Receptors, Opioid</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>465-65-6</RegistryNumber>
<NameOfSubstance>Naloxone</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>7440-23-5</RegistryNumber>
<NameOfSubstance>Sodium</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Animal</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Brain</DescriptorName>
<QualifierName>metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Endorphins</DescriptorName>
<QualifierName>blood</QualifierName>
<QualifierName>metabolism</QualifierName>
<QualifierName MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Gastrointestinal Motility</DescriptorName>
<QualifierName>drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Guinea Pigs</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Human</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Ileum</DescriptorName>
<QualifierName>drug effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Molecular Conformation</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Naloxone</DescriptorName>
<QualifierName>pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Psychotic Disorders</DescriptorName>
<QualifierName>blood</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Radioimmunoassay</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Receptors, Opioid</DescriptorName>
<QualifierName>drug effects</QualifierName>
<QualifierName>metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Sodium</DescriptorName>
<QualifierName>pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Support, U.S. Gov't, P.H.S.</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Vas Deferens</DescriptorName>
<QualifierName>drug effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
